Ultragenyx and Arcturus collaborate to develop mRNA therapeutics for rare diseases Nov. 2, 2015 No Comments
Arrowhead describes targeted RNAi therapeutics for HBV, renal cell carcinoma, cardiovascular disease Oct. 27, 2015 No Comments
Novo Nordisk licenses use of Emisphere's Eligen technology for oral drug development Oct. 19, 2015 No Comments
Rock Creek completes phase I trial of oral formulations of anatabine citrate Oct. 19, 2015 No Comments
RSS